Ionis Insider Files Form 4: 10,000-Share Sale Under 10b5-1 Plan
Rhea-AI Filing Summary
Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals (IONS), reported the sale of 10,000 shares of common stock on 09/02/2025. The shares were sold at a weighted average price of $50.3671 per share (individual trades ranged from $50.01 to $50.92). After the reported disposition, Mr. Geary beneficially owns 79,657 shares. The filing states the sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025, and the filer offers to provide trade-level detail on request.
Positive
- Sales executed under a Rule 10b5-1 trading plan, which indicates pre-scheduled, documented transactions
- Filer offers to provide trade-level breakdown of prices within the disclosed range upon request, increasing transparency
Negative
- Disposition of 10,000 shares reduces the reporting person's beneficial holdings to 79,657 shares
- Weighted average sale price reported instead of per-trade quantities and prices in the form itself (though breakdown is offered on request)
Insights
TL;DR: Insider sold a modest block of shares under a pre-established 10b5-1 plan; transaction appears procedural, not a sudden change in ownership.
Geary disposed of 10,000 shares at a weighted average of $50.3671, leaving 79,657 shares beneficially owned. The transaction was executed under a Rule 10b5-1 plan adopted May 6, 2025, which typically signals scheduled, non-discretionary sales. On its face this is a routine insider liquidity event rather than an extraordinary corporate development. Investors seeking granular timing or per-trade prices may request the breakdown the filer offered to provide.
TL;DR: Use of a 10b5-1 plan indicates compliance with insider trading rules; disclosure is complete about plan adoption and price range.
The Form 4 discloses the plan adoption date and a weighted average sale price with the reported per-trade price range, and the filer explicitly offers to supply detailed trade-level information on request. Those disclosures align with good governance and transparency practices for Section 16 reporting. The transaction reduces the officer's direct holdings to 79,657 shares but does not, by itself, indicate misuse of material nonpublic information.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 10,000 | $50.3671 | $504K |
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.01 to $50.92, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
